<DOC>
	<DOCNO>NCT00887588</DOCNO>
	<brief_summary>The study assess effect 36 week treatment LCZ696 compare valsartan N-terminal pro-Brain Natriuretic Peptide ( NT-proBNP ) patient chronic heart failure preserve left-ventricular ejection fraction .</brief_summary>
	<brief_title>LCZ696 Compared Valsartan Patients With Chronic Heart Failure Preserved Left-ventricular Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Patients document stable chronic heart failure ( NYHA IIIV ) : LVEF ≥ 45 % ( local measurement , assess echocardiography , MUGA , CT scan , MRI ventricular angiography ) ejection fraction must obtain within 6 month prior randomization MI event would affect ejection fraction . Plasma NTproBNP &gt; 500 pg/ml Visit 1 . Patients document stable chronic heart failure ( NYHA IIIV ) . Patients receive ACE inhibitor ( ACEi ) , angiotensin receptor blocker ( ARB ) and/or beta blocker must stable dose medication stable 1 month period prior Visit 1 . Patients must diuretic therapy prior Visit 1 ( flexible dosing permit ) . Patients control systolic BP , define target systolic BP le 140 mm Hg ; participant BP include 160 mm Hg eligible enrollment three medication control BP randomization ( Visit 2 ) . Patients least one follow symptoms time screen ( Visit 1 ) : Dyspnea exertion Orthopnea Paroxysmal nocturnal dyspnea Peripheral edema Patients must eGFR ≥ 30 ml/min/1.73 m2 Visit 1 ( calculate Modification Diet Renal Disease formula ) . Patients potassium ≤5.2 mmol/l Visit 1 . Patients prior LVEF reading &lt; 45 % , time . Patients require treatment ACE inhibitor ARB . Isolated right heart failure due pulmonary disease . Dyspnea and/or edema noncardiac cause , lung disease , anemia , severe obesity . Presence hemodynamically significant mitral /or aortic valve disease . Presence hemodynamically significant obstructive lesion leave ventricular outflow tract , include aortic stenosis . Presence hypertrophic obstructive cardiomyopathy . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Chronic heart failure</keyword>
	<keyword>preserve ejection fraction</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>NT-proBNP</keyword>
	<keyword>biomarkers</keyword>
	<keyword>Heart failure preserve left-ventricular ejection</keyword>
	<keyword>fraction</keyword>
</DOC>